Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations.

IF 3.7 4区医学 Q1 DERMATOLOGY

Acta dermato-venereologica Pub Date : 2025-10-02 DOI:10.2340/actadv.v105.43523

Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti, Giampiero Girolomoni, Simone Ribero, Luisa Boeti, Luca Bianchi, Maria Concetta Fargnoli, Giovanni Pellacani, Sabatino Pallotta, Ketty Peris, Marco Galluzzo

{"title":"Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations.","authors":"Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti, Giampiero Girolomoni, Simone Ribero, Luisa Boeti, Luca Bianchi, Maria Concetta Fargnoli, Giovanni Pellacani, Sabatino Pallotta, Ketty Peris, Marco Galluzzo","doi":"10.2340/actadv.v105.43523","DOIUrl":null,"url":null,"abstract":"<p><p>Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43523"},"PeriodicalIF":3.7000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta dermato-venereologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/actadv.v105.43523","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.

查看原文本刊更多论文

Dupilumab治疗特殊人群特应性皮炎的安全性和有效性分析。

Dupilumab是首个被批准用于中重度特应性皮炎的生物治疗药物，它彻底改变了这种疾病的治疗方法，允许长期控制其临床体征和症状。然而，关于dupilumab在特殊人群患者中的安全性和有效性的数据很少。这项观察性多中心研究分析了dupilumab治疗70例中度至重度特应性皮炎及相关合并症（如癌症、肾衰竭和肝功能衰竭、病毒性慢性感染、退行性和自身免疫性神经系统疾病）患者3年以上的有效性和安全性。在16周的治疗后，患者在医生评估和患者报告的结果方面都取得了显著的改善，并在156周的治疗期间保持了持续的治疗反应。安全性与临床试验和无显著合并症患者的真实世界数据相当。总之，研究结果支持dupilumab治疗脆弱患者严重特应性皮炎的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta dermato-venereologica 医学-皮肤病学

CiteScore

4.90

自引率

2.80%

发文量

210

审稿时长

6-12 weeks

期刊介绍： Acta Dermato-Venereologica publishes high-quality manuscripts in English in the field of Dermatology and Venereology, dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of Review articles in special areas, as well as short Letters to the Editor to stimulate debate and to disseminate important clinical observations. Acta Dermato-Venereologica has rapid publication times and is amply illustrated with a large number of colour photographs.